A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
A phase 3 trial of Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide and Carboplatin in HR-positive / HER2-negative breast cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer is a phase 3 interventional study registered as NCT06112379 by AstraZeneca, with 1902 participants enrolled, started 2023-11-14 and due to reach its primary completion in 2028-11-20. Interventions recorded: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin and Cyclophosphamide.
Similar pages
not linked directly; found by shared links- TrialStudy of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Shares Epirubicin, Daiichi Sankyo, Cyclophosphamide, Doxorubicin and the tag pipeline.
- TrialStudy of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
Shares Epirubicin, Cyclophosphamide, Doxorubicin, Pembrolizumab and the tag pipeline.
- TrialA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Shares Epirubicin, Cyclophosphamide, Doxorubicin, Carboplatin and the tag pipeline.
- TrialA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Shares Daiichi Sankyo, AstraZeneca, HR-positive / HER2-negative breast cancer and the tag pipeline.
- TrialAn Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Shares Daiichi Sankyo, Durvalumab, AstraZeneca, Pembrolizumab and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Durvalumab, AstraZeneca, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Shares Durvalumab, AstraZeneca, Carboplatin, Pembrolizumab and the tag pipeline.
- TrialTo Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Shares Epirubicin, Cyclophosphamide, HR-positive / HER2-negative breast cancer and the tag pipeline.